Evidence map›Paper›PMID 29113770›Full record

ArticleClinical genitourinary cancer2018

Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.

Juan Chipollini, E Jason Abel, Charles C Peyton, David C Boulware, Jose A Karam, Vitaly Margulis, Viraj A Master, Kamran Zargar-Shoshtari, Surena F Matin, Wade J Sexton and 3 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Juan ChipolliniMoffitt Cancer Center, Tampa, FL. Electronic address: juan.chipollini@moffitt.org.
E Jason AbelUniversity of Wisconsin School of Medicine and Public Health, Madison, WI.
Charles C PeytonMoffitt Cancer Center, Tampa, FL.
David C BoulwareMoffitt Cancer Center, Tampa, FL.
Jose A KaramUniversity of Texas MD Anderson Cancer Center, Houston, TX.
Vitaly MargulisUniversity of Texas Southwestern Medical Center, Dallas, TX.
Viraj A MasterEmory Clinic, Atlanta, GA.
Kamran Zargar-ShoshtariAuckland City Hospital, Auckland, Australia.
Surena F MatinUniversity of Texas MD Anderson Cancer Center, Houston, TX.
Wade J SextonMoffitt Cancer Center, Tampa, FL.
Jay D RamanDivision of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA.
Christopher G WoodUniversity of Texas MD Anderson Cancer Center, Houston, TX.
Philippe E SpiessMoffitt Cancer Center, Tampa, FL.
Moffitt Cancer Center · USThe University of Texas MD Anderson Cancer Center · USEmory Clinic · USPenn State Milton S. Hershey Medical Center · USThe University of Texas Southwestern Medical Center · USUniversity of Wisconsin–Madison · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

purposeTo determine the therapeutic value of lymph node dissection (LND) during cytoreductive nephrectomy (CN) and assess predictors of cancer-specific survival (CSS) in metastatic renal-cell carcinoma. PATIENTS AND

methodsWe identified 293 consecutive patients treated with CN at 4 academic institutions from March 2000 to May 2015. LND was performed in 187 patients (63.8%). CSS was estimated by the Kaplan-Meier method for the entire cohort and for a propensity score-matched cohort. Cox proportional hazards regression was used to evaluate CSS in a multivariate model and in an inverse probability weighting-adjusted model for patients who underwent dissection.

resultsMedian follow-up was 12.6 months (interquartile range, 4.47, 30.3), and median survival was 15.9 months. Of the 293 patients, 187 (63.8%) underwent LND. One hundred six patients had nodal involvement (pN+) with a median CSS of 11.3 months (95% confidence interval [CI], 6.6, 15.9) versus 24.2 months (95% confidence interval, 14.1, 34.3) for pN- patients (log-rank P = .002). The hazard ratio for LND was 1.325 (95% CI, 1.002, 1.75) for the whole cohort and 1.024 (95% CI, 0.682, 1.537) in the propensity score-matched cohort. Multivariate analysis revealed that number of positive lymph nodes (P < .001) was a significant predictor of worse CSS.

conclusionFor patients with metastatic renal-cell carcinoma undergoing CN with lymphadenectomy, the number of nodes positive was predictive of survival at short-term follow-up. However, nonstandardized lymphadenectomy only provided prognostic information without therapeutic benefit. Prospective studies with standardized templates are required to further ascertain the therapeutic value of LND.

Indexed as

AgedCarcinoma, Renal CellCytoreduction Surgical ProceduresFemaleHumansKidney NeoplasmsLymph Node ExcisionMaleMiddle AgedNephrectomyPropensity ScoreProspective StudiesRetrospective StudiesSurvival AnalysisCytoreductive nephrectomyLymphadenectomyLymph node dissectionMetastatic renal cell carcinomaNode density

Identifiers

PMID29113770
PMCPMC7771342
OpenAlexW2766729486

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.